Defensive rotation: Dow hits record highs while tech bleeds — accumulate Eli Lilly
The old-school Dow Jones hit a record high thanks to defensive stocks like Eli Lilly, while tech stocks took a hit. With the economy slowing down and unemployment ticking up, investors are moving their money into healthcare companies whose sales are protected by government Medicare coverage.
Idea
While the tech-heavy Nasdaq is falling due to chip struggles, the Dow Jones hit a record high, signaling a classic rotation into defensive sectors. Eli Lilly just hit new highs thanks to huge results and Medicare inclusion for its GLP-1 drugs, insulating its revenue from economic downturns. With only 57,000 jobs added in June and unemployment rising to 4.2%, the economy is clearly cooling off. Buying dominant healthcare names like Eli Lilly protects a portfolio during an economic slowdown while the government-backed Medicare inclusion guarantees steady sales.
Advanced Analysis — institutional-depth research report
Verdict: Eli Lilly's fundamentals deserve respect, but the entry hasn't earned a trade yet
The defensive-rotation case has real substance: FY2025 revenue was $65.2B, up 44.7% year over year, net income reached $20.6B at a 31.7% margin, and the dividend has grown roughly 15.3% annually to a trailing $6.69 per share — elite economics for a supposed defensive name. But the strongest point against is that the compiled rules produced zero entries across 60, 24, and 12-month windows on 1,232 real daily bars, and the parameter-sensitivity evaluation ran out of time, so no robust parameter setup was established; the strategy also expresses a technical reversal on QQQ rather than the healthcare-rotation thesis itself. The latest quarter cuts both ways — gross margin rose 3.8 points to 85.8%, but net margin fell 6.5 points to 30.9% and ROE slipped from 23.7% to 20.9%. Meanwhile, the ownership filing covering the period ended June 30, 2026 (a lagged view, not current) shows insiders as net open-market sellers by roughly $2.9M, the opposite of conviction buying. Nothing is live to buy: LLY last closed at $1,129.76, $62.55 below the $1,192.31 20-day average that is the only unmet entry condition, while RSI (14) at 31.9 already clears the at-or-below-40 gate and first support sits at $1,110.57. A confirmed close above the 20-day average with the other conditions intact — or a stabilized margin line in the late-October Q3 report — would flip this from watch-list to actionable; thesis support and fundamentals trend score moderately well, but trade readiness and trigger proximity stay low until the threshold confirms.
Trade now: LLY entry is one condition away — here's the exact level
Nothing to buy yet — this is a watch-list setup, and the plan is to let the entry come to you. LLY last closed at $1,129.76, sitting between first support at $1,110.57 and first resistance at $1,134.31. Three of the four entry conditions are already live: the 20-day channel condition is met, RSI (14) is at 31.9 versus the at-or-below-40 threshold (cleared by 8.1 points), and the down-close-versus-open condition resolves on the daily bar itself. The one blocker is structural: price needs to be above the 20-day average, currently $1,192.31 — that's $62.55 above the last close. So waiting means exactly this: LLY either recovers above roughly $1,192 while momentum stays below 40 and tags but holds first support, or there is no entry. On fills, the mechanics are fixed. The stop is a 2.4% loss on the position; the profit target is 4.8%, and a close at or above first resistance also exits long. That gives an effective reward-to-risk of about 2-to-1 on any triggered entry, with position risk capped at roughly 2.4% of account under the fixed-risk sizing rule and a 25% maximum position. A close back above first support ($1,110.57) after crossing below it is a secondary stop exit. Context on why the entry is worth waiting for: the idea argues that defensive rotation — Dow record highs on the back of healthcare names like Eli Lilly while the Nasdaq bleeds — protects capital in a cooling economy, with Medicare inclusion for GLP-1 drugs cited as the revenue backstop. The latest quarter supports the margin story (gross margin rose to 85.8%, up 3.8 points quarter over quarter) but also shows net margin compressing to 30.9% from 37.4%, a 6.5-point drop. That mix argues against chasing: let the price condition, not the headline narrative, decide the entry. Insiders were net open-market sellers by about $2.9M in the most recent ownership filing covering the period ended June 30, 2026, which reinforces the case for waiting for a technically defined level rather than buying conviction outright.
The bull case still has support
The idea's defensive-rotation thesis has real fundamental support. Eli Lilly's full-year 2025 revenue was $65.2B, up 44.7% year over year, with a gross margin of 83.0% and net income of $20.6B — a 31.7% net margin. The momentum continued into 2026: Q2 revenue reached $22.97B (up from $19.80B in Q1) and quarterly…
Scores
- Conviction score breakdown: 48
- Thesis support: 70
- Trade readiness: 25
- Risk quality: 55
- Trigger proximity: 30
- Fundamentals trend: 60
Watch items
- LLY — LLY daily close vs SMA (20)
- LLY — RSI (14)
- LLY — First support level
- LLY — Insider net open-market value (next ownership filing after 2026-06-30)
- LLY — Net margin, Q3 (period ending 2026-09-30)